Streetbeat News

Stock Prices

BONKUSD

DOGEUSD

PEPEUSD

SHIBUSD

Bonk and Pepe, two meme coins, have seen significant weekly gains of 23.5% and 17.6% respectively, outperforming Dogecoin and Shiba Inu. The rally is attributed to Bitcoin's surge to $50,000. Bitstamp's listing of Pepe and bullish social media analysis further spotlight these coins. Despite their popularity, meme coins on the Solana network, like Bonk and Pepe, face volatility due to profit-taking. Dogwifhat, another Solana meme coin, has also seen an 80% weekly gain.

Portfolio Pulse from Khyathi Dalal

February 13, 2024 | 7:21 pm

EXAI

Exscientia Plc (NASDAQ:EXAI) terminated CEO Andrew Hopkins due to inappropriate relationships with employees. Chief Science Officer Dave Hallett steps in as interim CEO. Chairman David Nicholson resigned after it was revealed he knew of Hopkins' conduct. EXAI shares dropped 19.80% to $6.02.

Portfolio Pulse from Vandana Singh

February 13, 2024 | 7:17 pm

ALLY

Shares of companies in the financial sector are down after January CPI data indicated a higher-than-expected inflation rise, creating uncertainty about future rate cuts.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 7:17 pm

ABCB

BAC

Bank stocks including ABCB, ASB, AUB, BAC, and others traded lower after January's CPI data indicated a higher-than-expected inflation rise, casting doubt on future rate cuts.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 7:16 pm

CVS

Deep-pocketed investors are showing a bearish sentiment towards CVS Health (NYSE:CVS), with a notable shift in options trading activity. Benzinga's tracking revealed 8 extraordinary options activities, with a bearish majority among investors. The trading focuses on a price band between $35.0 and $76.0. Significant options trades include both calls and puts with varying sentiments and expiration dates. CVS Health, a major healthcare services provider, is currently trading down by -0.89% at $76.6. Analyst ratings in the last month have set an average target price of $85.5 for CVS.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:15 pm

KKR

Recent options activity for KKR & Co (NYSE:KKR) shows a bearish sentiment among investors, with 55% of trades being bearish. The options trades target a price range of $70.0 to $120.0. KKR, a major asset manager with $518.5 billion in AUM, is currently trading at $96.02, down by -1.64%. Analysts have issued mixed ratings, with a consensus target price of $96.5. The notable options activity and analyst ratings suggest a cautious outlook for KKR's stock in the short term.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:15 pm

BIIB

IWM

SSRM

TLT

Wall Street experienced significant declines due to a higher-than-expected inflation report, leading to adjustments in rate cut expectations and a surge in Treasury yields. The iShares 20+ Year Treasury Bond ETF (TLT) and iShares Russell 2000 ETF (IWM) saw notable drops. Bitcoin, gold, and major indices also fell. Biogen Inc. (BIIB) and SSR Mining Inc. (SSRM) were among the biggest losers due to earnings misses and operational issues, respectively.

Portfolio Pulse from Piero Cingari

February 13, 2024 | 7:13 pm

TSLA

Tesla Inc (TSLA) is under scrutiny after Hans von Ohain, a Tesla recruiter, died in a crash involving the company's full self-driving feature. Despite high blood alcohol levels, the incident raises questions about the safety and reliability of Tesla's autonomous driving technology. The accident, which Tesla reported to the NHTSA, has not been publicly acknowledged by the company. Over 900 accidents involving Tesla's driver-assistance systems have been reported since 2021, highlighting ongoing safety concerns.

Portfolio Pulse from Chris Katje

February 13, 2024 | 7:11 pm

ALT

LLY

NVO

Altimmune, Inc (NASDAQ:ALT) shares dropped after Kerrisdale Capital announced a short position, criticizing the potential of Altimmune's drug pemvidutide compared to competitors like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. Kerrisdale highlighted concerns over pemvidutide's efficacy, tolerability, and the challenging competitive landscape.

Portfolio Pulse from Adam Eckert

February 13, 2024 | 7:05 pm

CBAY

GILD

ICPT

Gilead Sciences Inc (GILD) has agreed to acquire CymaBay Therapeutics Inc (CBAY) for $4.3 billion, aiming to enhance its liver disease portfolio with CymaBay's seladelpar for primary biliary cholangitis (PBC). Despite the acquisition not being a major game-changer for Gilead, it's seen as a low-risk move that leverages Gilead's strong commercial capabilities in liver diseases. Seladelpar's potential in addressing pruritus could differentiate it in the PBC market. Baird maintains a Neutral rating on GILD with an $80 price target.

Portfolio Pulse from Vandana Singh

February 13, 2024 | 7:05 pm